The use of erythropoietin and its derivatives to treat Spinal Cord injury

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 9, 2011, Pages 763-770

  Mofidi, A ^a   Bader, A ^a   Pavlica, S ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Asialo epo; Carbamylated epo; Epo derivatives; Erythropoietin; Recombinant human erythropoietin; Spinal cord injury

Indexed keywords

ASIALO ERYTHROPOIETIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMYLATED ERYTHROPOIETIN; CICLOPIROXOLAMINE; COBALT CHLORIDE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DEFEROXAMINE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FG 2216; FG 4592; GLYCOGEN SYNTHASE KINASE 3BETA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; NEUROPROTECTIVE AGENT; NEUROTROPHIN; PHOSPHATIDYLINOSITOL 3 KINASE; RECOMBINANT ERYTHROPOIETIN; STAT5 PROTEIN; TM 6008; TM 6009; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; CARBAMOYLATION; CELL PROLIFERATION; COMPETITIVE INHIBITION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; ERYTHROPOIESIS; EXPERIMENTAL MODEL; HEMATOCRIT; HUMAN; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD INJURY;

ERYTHROPOIETIN; HUMANS; NEUROPROTECTIVE AGENTS; RECOMBINANT PROTEINS; SPINAL CORD INJURIES;

EID: 79960594292     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711796355267     Document Type: Review

References (84)

1. Matia, G.K.; Birbills, T.A. Erythropoietin in Spinal cord Injury. Eur. Spine J., 2009, 18, 314-323.
2. Swain, A.; Grundy, D. In ABC of Spinal Cord Injury; Grundy, D.; Swain, A.; BMJ books B.V: London, 2002; vol. 4, pp. 1.
3. Brines, M.; Cerami, A. In Erythropoietin and the nervous system; Höke, A.; Springer B.V: New York, 2006; pp. 147-164.
4. Kwon, B.K.; Borissoff, J.F.; Tatzlaff, W. Molecular targets for therapeutic intervention after spinal cord injury. Mol. Interv., 2002, 2, 244-258.
5. Hock, N.H. Neuroprotective agents in acute ischemic stroke. J. Cardiovasc. Nurs., 1998, 13, 17-25.
6. Profyris, C.; Cheema, S.S.; Zang, D.; Azari, M.F.; Boyle, K.; Petratos, S. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol. Dis., 2004, 15, 415-436.
7. King, V.R.; Averill, S.A.; Hewazy, D.; Piestley, J.V.; Torup, L.; Michael-Titus, A.T. Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the Rat. Eur. J. Neuroscince, 2007, 26, 90-100.
8. Kamenic, H.; Griebel, R.W.; Lyon, A.W. Paterson, P.G.; Juurlink, B.H. Promoting Glutathione synthesis after spinal cord trauma decreases secondary damage and promotes retention of function. FASEB. J., 2001, 15, 243-250.
9. Gorio, A.; Madaschi, L.; Di Stefano, B.; Carelli, S.; Di Giulio, A.M.; De Biasi, S.; Coleman, T.; Cerami, A.; Berines, M. Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 16379-16384.
10. Leist, M.; Ghezzi, P.; Grasso, G.; Bianchi, R.; Villa, P.; Fratelli, M.; Savino, C.; Bianchi, M.; Nielsen, J.; Gerwien, J.; Kallunki, P.; Larsen, A.K.; Helboe, L.; Christensen, S.; Pedresen, L.O.; Nielsem, M.; Torup, L.; Sager, T.; Stacteria, A.; Erbayraktar, S.; Erbayraktar, Z.; Gokmen, N.; Yilmaz, O.; Ceramic-Hand, C.; Xie, Q.W.; Colman, T.; Cerami, A.; Brines, M. Derivatievs of erythropoietin that are tissue protective but not erythropoietic. Science, 2004, 305, 239-242.
11. Cetin, A.; Nas, K.; Buyukbayram, H.; Ceviz, A.; Olmez, G. The effects of systemically administered methylprednisolone and recombinant human erythropoietin after acute spinal cord compressive injury in rats. Eur. Spine J., 2006, 15, 1539-1544.
12. [Montero, M.; Mpoulsen, F.R.; Noraberg, J.; Kirkeby, A.; Van Beek, J.; Leist, M.; Zimmer, J. Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA ecitotoxicity in mouse hippocampal slice culture. Exp. Neurol., 2007, 204,106-17.
13. Zhang, W.; Sun, B.; Yu. Z.; An, J.; Liu, Q.; Ren, T.; High dose erythropoietin promotes functional recovery of rats following facial nerve crush. J. Clin. Neurosci., 2009, 16, 554-556.
14. Rees, S.; Hale, N.; De Matteo, R.; Cardamone, L.; Tolcos, M.; Loeliger, M.; Mackintosh, A.; Shields, A.; Probyn, M.; Greenwood, D.; Harding, R. Erythropoietin is neuroprotective in a preterm ovine model of endotoxin induced. J. Neuropathol. Exp. Neurol., 2010, 69, 306-319.
15. Dzietko, M.; Felderhoff-Mueser, U.; Sifringer, M.; Krutz, B.; Bittigau, P.; Thor, F.; Heumann, R.; Buerer, C.; Ikonomidou, C.; Hansan, H.H. Erythropoietin protects the developing brain against Nmethyl- D-aspartate receptor antagonists neurotoxicity. Neurobiol. Dis., 2004, 15,177-187.
16. Smithe, P.D.; Puskas, F.; Fullertin, D.A.; Meng, X.; Chon, D.; Clevand, J.C.; Wwvant, M.J.; Reece, T.B. Attenuation of spinal cord ischemia and reperfusion injury by erythropoietin. J. Thorac. Cardiovasc. Surg., 2011, 141, 256-260.
17. Celik, M.; Gökmen, N.; Erbayraktar, S.; Akhisaroglu, M.; Ulikus, C.; Genc, S.; Genc, K.; Sagiroglu, E.; Cerami, A.; Brines, M. Erythropoietin prevent s motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc. Natl. Acad. Sci. USA, 2002, 99, 2258-2263.
18. Carnot, C.; DeFlandre, C. Sur 1' activite hemopoietique du serum au cours de la regeneration du sang. C.R. Acad. Sci. Paris, 1906, 143, 432-435.
19. Kasper, C. In The cytokine handbook; Tomson, A.W.; Lotze, M.T.; Elsevier B.V: London, 2006; vol. 4, pp. 149-166.
20. Hjort, E. Reticulocyte increase after injection of anemic serum. Nor. Mag. Laegevidensk., 1936, 97, 270-277.
21. Krumdieck, N. Erythropoietic substance in the serum of anemic animals. Proc. Soc. Exp. Biol. Med., 1943, 54, 14-17.
22. Erslev, A. Humoral regulation of red cell production. Blood, 1953, 8, 349-357.
23. Bonsdorf, E.; Jalavisto, E. A humoral mechanism in anoxic erythrocytosis. Acta. Physiol. Scand. 1948, 16,150-170.
24. Watkins, P.C.; Eddy, R.; Hoffman, N.; Stanislovitis, P.; Beck, A.K.; Galli, J.; Vellucci, V.; Gusella, J.F.; Shows, T.B. Regional assignment of the erythropoietin gene to human chromosome region 7peter-q22. Cytogenet. Cell Genet, 1986, 42, 214-218.
25. Lin, F.K.; Suggs, S.; Lin C.H.; Browne, J.K.; Smalling, R.; Egrie, J.C.; Chen, K.K.; Fox, G.M.; Martin, F.; Stabinsky, Z.; Badrawi, S.M.; Lai, P.H.; Goldwasser, E. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA, 1985, 82, 7580-7584.
26. Jelkmann, W. Erythropoietin: structure, control of production and function. Physiol. Rev., 1992, 72, 449-489.
27. Lykissas, M.G.; Korompilias, A.V.; Vekris, M.D.; Mitsionis, G.I.; Sakellariou, E.; Beris, A.E. The role of erythropoietin in central and peripheral nerve injury. Clin. Neurol. Neurosur., 2007,109, 639-644.
28. Bartesaghi, S.; Marionvich, M.; Corsini, E.; Galli, C.L.; Viviani, B. Erythropoietin: A novel neuroprotective cytokine. Neurotoxicol., 2005, 26, 923-928.
29. Keswani, S.C.; Buldanlioglu, U.; Fischer, A.; Reed, N.; Polley, M.; Liang, H.; Zhou, C.; Jack, C.; Leitz, G.J.; Hoke, A. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann. Neurol., 2004, 56, 815-826.
30. Toth, C.; Martinez, J.A.; Liu, W.Q.; Diggle, J.; Guo, G.F.; Ramji, N.; Mi, R.; Hoke, A.; Zochodne, D.W. Local erythropoietin signaling enhances regeneration in peripheral axons. Neuroscience, 2008, 154, 767-783.
31. Li, Y.; Juul, S.E.; Morris-Wiman, J.A.; Calhoun, D.A.; Christensen, R.D. Erythropoitin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr. Res. 1996, 40, 376-380.
32. Nagai, A.; Nakagawa, E.; Choi, H.B.; Kobayashi, S.; Kim, S.U. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia and oligodendrocytes grown in culture. J. Neuropathol. Exp. Neurol., 2001, 60, 386-392.
33. Bader, A.; Lorenz, K.; Richter, A.; Scheffler K.; Kern, L.; Ebert, S.; Giri, S.; Behrens, M.; Dornseifer, U.; Macchiarini, P.; Machens, H.G. Interactive role of trauma cytokines and erythropoietin and their therapeutic potential for acute and chronic wounds. Rejuvenation Res.,2011,14,57-66.
34. Winkelmann, J.C.; Penny, L.A.; Deaven, L.L.; Forget, B.G.; Jenkins, R.B. The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p. Blood, 1990, 76, 24-30.
35. Viviani, B.; Bartesaghi, S.; Corsini, E.; Villa, P.; Ghezzi, P.; Garau, A.; Galli, C.L.; Marinovich, M. Erythropoietin protects primary hipocampal neurons increasing the expression of brain-derived neurotrophic factor. J. Neurochem. 2005,93,412-21.
36. Sakanaka, M.; Wen, T.C.; Matsuda, S.; Morishita, E.; Nagao, M.; Sasaki, R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 4635-4640.
37. Morishita, E.; Masuda, S.; Nagao, M.; Yasuda, Y.; Sasaki, R. Erythropoietin receptor is expressed in rat hipocampal and cerebral cortical neurons and erythropoietin prevents in vitro glutamate induced neuronal death. Neurosci., 1997, 76,105-116.
38. Yamaji, R.; Okada, T.; Moriya, M.; Naito, M.; Tsuruo, T.; Miyatake, K.; Nakano, Y. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur. J. Biochem., 1996, 239, 494-500.
39. Digicaylioglu, M.; Lipton, S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappa B signaling cascades. Nature, 2001, 412,641-647.
40. Arcasoy, M.O. The non-hematopoietic biological effects of erythropoietin. Br. J. Haematol., 2008, 141, 14-31.
41. Siren, A.L.; Fratelli, M.; Brines, M.; Goemans, C.; Casagrande, S.; Lewczuk, P.; Keenan, S.; Gleiter, C.; Pasquali, C.; Capobianco, A.; Mennini, T.; Heumann, R.; Cerami, A.; Ehrenreich, H.; Ghezzi, P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and in metabolic stress. Proc. Natl. Acad. Sci. USA, 2001, 98, 4044-4049.
42. Brines, M.; Cerami, A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci., 2005, 6, 484-494.
43. Byts, N.; Samoylenko, A.; Fasshauer, T.; Ivanisevic, M.; Hennighausen, L.; Ehrenreich, H.; Sirén, A.L. Essential role for Stat5 in the neurotrophic but not in neuroprotective effect of erythropoietin. Cell Death Differ., 2008,15, 783-792.
44. Bao, H.; Jacobs-Helber, S.M.; Lawson, A.E.; Penta, K.; Wickrema, A.; Sawyer, S.T. Protein kinase B (c-AKt), phosphatidylinositol 3- kinase and STAT-5 areactivated by erythropoietin (EPO)in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood, 1999, 93, 3757-3773.
45. Bhat, R.V.; Shanley, J.; Correll, M.P.; Fieles, W.E.; Keith, R.A.; Scott, C.W.; Lee, C.M. Regulation and localization of tyrosine216 phosphoeylation of glycogen synthase kinase-3?? in cellular and animal models of neuronal regeneration. Proc. Natl. Acad. Sci. USA, 2000, 97, 11074-11079.
46. Xiong, Y.; Mahmood, A.; Qu; C.; Kazmi, H.; Zhang, Z.G.; Noguchi, C.T.; Schallert, T.; Chopp, M. Erythropoietin Improves Histological and Functional Outcomes after Traumatic Brain Injury in Mice in the Absence of the Neural Erythropoietin Receptor. J. Neurotrauma, 2009, 27,205-215.
47. Tsai, PT.; Ohab, J.J.; Kertesz, N.; Groszer, M.; Matter, C.; Gao, J.; Liu, X.; Wu, H.; Carmichael, S.T. A critical role of erythropoietin receptor in neurogenesis and pot-stroke recovery. J. Neurosci., 2006, 4, 1269-1274.
48. Grasso, G.; Sfacteria, A.; Erbayraktar, S.; Passalacqua, M.; Meli, F.; Gokmen, N.; Yilmaz, O.; La Torre, D.; Buemi, M.; Iacopino, D.G.; Coleman, T.; Cerami, A.; Brines, M.; Tomasello, F. Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and nonerythropoietic erythropoietin derivative. J. Neurosurg. Spin., 2006, 4,310-318.
49. Arishima, Y.; Setoguchi, T.; Yamaura, I.; Yone, K.; Komiya, S. Preventive effect of erythropoietin on spinal cord cell apoptosis following acute traumatic injury in rats. Spine, 2006, 31, 2432-2438.
50. Boran, B.O.; Colak, A.; Kutlay, M. Erythropoietin enhances neurological recovery after experimental spinal cord injury. Restor. Neurol. Neurosci., 2005, 23, 341-345.
51. Okutan, O.; Solaroglu, I.; Beskonakli, E.; Taskin, Y. Recombinant human erythropoietin decrease myeloperoxidase and caspase-3 activity and improves early functional results after spinal cord injury in rats. J. Clin. Neurosci., 2007, 14, 364-368.
52. Miyake, T.; Kung, C.K.; Goldwasser, E. Purification of human erythropoietin. J. Biol. Chem., 1977, 252, 5558-5564.
53. Jelkmann, W. Biosimilar epoetin and other "follow on" biologics: update on the European experiences. Am. J. Hematol., 2010, 85, 771-780.
54. Kontogeogakos, V.A.; Voulgaris, S.; Korompilias, A.V.; Plolyzoidis, K.S.; Bourantas, K.; Beris, A.E. The efficacy of erythropoietin on acute spinal cord injury. An experimental study on a rat model. Arch. Orthop. Trauma. Surg., 2009, 129, 189-194.
55. Kaptanoglu, E.; Solaroglu, I.; Okutan, O.; Surucu, H.S.; Akbiyik, F.; Beskonakli, E. Erythropoietin exert neuroprotection afret acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg. Rev., 2004, 21, 113-120.
56. Smith, P.D.; Puskas, F.; Fullerton, D.A.; Megn, X.; Cho, D.; Cleverland, J.R.; Weyant, M.Y.; Reece, T.B. Attenuation of spinal cord ischemia and reperfusion injury by erythropoietin. J. Thorac. Cardiovasc. Surg., 2011, 141, 256-260.
57. Chong, Z.Z.; Kang, J.Q.; Maiese, K. Erythropoietin forester both intrinsic neuronal protection through modulation of microglia. Akt-1. Bad, caspase-mediated pathways. Br. J. Pharmacol., 2003, 138, 1107-1118.
58. Chong, Z.Z.; Lin, S.H.; Maiese, K. Nicotinamide modulates mitochondrial membrane potential and cystein protease activity during cerebral vascular endothelial cell injury. J. Vasc. Res., 2002, 39,131-147.
59. Kennedy, S.G.; Kandel, E.S.; Cross, T.K.; Hay, N. AKt/Protein kinase B inhibits cell death by preventing the release of cytochrome C from mitochondria. Mol. Cell Biol., 1999, 19, 5800-5810.
60. Mandal, D.; Moitra, P.K.; Saha, S.; Basu, J. Caspase 3 regulates phosphatidylserin externalization and phagocytosis of oxidatively stressed erythrocytes. FEBS Lett., 2002, 513, 184-188.
61. Villa, P.; Bigini, P.; Mennini, T.; Agnello, D.; La ragione, T.; Cgnotto, A.; Viviani, B.; Marinovich, M.; Cerami, A.; Coleman, T.R.; Brines, M.; Ghezzi, P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J. Exp. Med., 2003,198, 971-975.
62. Siren, A.N.; Fasshauer, T.; Bartels, C.; Ehrenreich, H. Therapeutic potential of Erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics, 2009, 16, 108-127.
63. Grasso, G.; Sfacteria, A.; Passalaqua, M.; Morabito, A.; Buemi, M.; Macri, B.; Brines, M.L.; Tomasello, F. Erythropoietin and erythropoietin receptor expression after experimental spinal cord injury encourages therapy by exogenous erythropoietin. J. Neurosurgery, 2005, 56, 821-827.
64. Brines, M.; Cerami, A. In Erythropoietin and the nervous system. Hoke, A.; Springer B: V: New York, 2006; pp. 147-164.
65. Erbayraktar, S.; Grasso, G.; Sfacteria, A.; Xie, Q.W.; Coleman, T.; Torup, L.; Kreilgaard, M.; Sager, T.; Erbayraktar, Z.; Gokmen, N.; Yilmaz, O.; Ghezzi, P.;Villa, P.; Fratelli, M.; Casagrande, S.;Leist, M.; Helboe L.; Gerwein, J.; Christensen, S.; Geist, M.A.; Pedersen, L.Ø.; Cerami-Hand, C.; Wuerth, J.P.; Cerami, A.; Brines, M. Asialoerythropoieten is a nanerytheopoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 6741-6746.
66. Wen, D.; Boissel, J.P.; Showers, M.; Ruch, B.C.; Bunn, H.F. Erythropoietin structure-function relationship. Identification of functional important domains. J. Biol. Chem., 1994, 269, 22846-22893.
67. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami, A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc. Nat.l Acad. Sc.i U. S. A., 2008, 105,10925-10930.
68. Browne, J.K; Cohen, A.M.; Eqrie, J.C.; Lar, P.H.; Lim, F.K.; Strickland, T.; Watson, E.; Stebbing, N. Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb. Symp. Quant. Biol., 1986, 51, 693-702.
69. Villa, P.; Van Beek, J.; Larsen, A.K.; Gerwien, J.; Christensen, S.; Cerami, A.; Brines, M.; Leist, M.; Ghezzi, P.; Torup, L. Reduced functional deficits, neuroinflammation and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J. Cereb. Blood Flow Metab., 2007, 25, 52-63.
70. Kitamura, T.; Tojo, A.; Kuwaki, T.; Chiba, S.; Miyazono, K.; Urabe, A.; Takaku, F. Identification and analysis of heuman erythropoietin receptors on a factor-dependent cell line, TF-1. Blood, 1989, 73, 375-80.
71. Montero, M.; Poulsen, F.R.; Noraberg, J.; Kirkeby, A.; Van Beek, J.; Leist, M.; Zimmer, J. Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures. Exp. Neurol., 2007, 204, 106-117.
72. Migliaccio, A.R.; Jiang, Y.; Migliaccio, G.; Nicolis, S.; Crotta, S.; Ronchi, A.; Ottolenghi, S.; Adamson, J.W. Transcriptional and posttranscriptional regulation of the expression of the erythropoietin receptor gene in human erythropoietin-responsive cell line. Blood. 1993, 82, 3760-3769.
73. Brines, M.; Grasso, G.; Fiordaliso, F.; Sfacteria, A.; Ghezzi, P.; Fratelli, M.; Latini, R.; Xie, Q.W.; Smart, J.; Su-Rick, C.J.; Pobre, E.; Diaz, D.; Gomez, D.; Hand, C.; Coleman, T.; Cerami, A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 14907-14912.
74. Mennini, T.; De paola, M.; Bigini, P.; Mastrotto, C.; Fumagalli, E.; Barbera, S.; Mengozzi, M.; Viviani, B.; Corsini, E.; Marinovich, M.; Torup, L.; Van Beek, J.; Leist, M.; Brines, M.; Cerami, A.; Ghezzi, P. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. J. Mol Med. 2006, 12, 153-160.
75. Xiong, Y., Mahmood, A., Zhang, Y., Meng, Y., Zhang, Z.G., Qu, C., Sager, T.N., hopp, M., Effects of posttraumatic carbamylated erythropoietin therapy on reducing lesion volume and hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome in rats following traumatic brain injury. J. Neurosurg, 2011, 114, 549-559.
76. Blake, T.; Jenkins, B.J.; D'Andrea, R.J.; Gonda, T.J. Functional cross talk between cytokine receptors revealed by activationg mutations in the extracellular domain of the β-subunit of the GM-CSF receptor. J. Leuk. Biol., 2002, 72, 1246-1255.
77. [Warren Pharmaceuticals (Pharmaceuticals W). Novel carbamylated epo and method for its production. WO2006/014466.
78. Lapchak, P.A. Carbamylated erythropoietin to treat neuronal injury: new development strategies. Expert Opin. Investig. Drugs, 2008, 17, 1157-1186
79. Rodríguez Cruz, Y.; Mengana Támos, Y.; Muñoz Cernuda, A.; Subirós Martines, N.; González-Quevedo, A.; Sosa Testé, I.; García Rodríguez, J.C. Treatment with nasal neuro-EPO improves the neurological, cognitive, and histological state in a gerbil model of focal ischemia. Scientific World J., 2010, 10, 2285-2287.
80. Stroka, D.M.; Burkhardt, T.; Desbaillets, I.; Wenger, R.H.; Neil, D.A.H.; Bauer, C.; Gassmann, M.; Candinas, D. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB. J., 2001, 15, 2445-2453.
81. Milosevic, J.; Adler, I.; Manaenko, A.; Schwarz, S.C.; Walkinshaw, G.; Arend, M.; Flippin, L.A.; Storch, A.; Schwarz, J. Nonhypoxic stabilization of hypoxia-inducible factor alpha (HIFalpha): relevance in neural progenitor/stem cells. Neurotox. Res., 2009, 15, 367-380.
82. Nangaku, M.; Izuhara, Y.; Takizawa, S.; Yamashita, T.; Fujii- Kuriyama, Y.; Ohneda, O.; Yamamoto, M.; van Ypersele de Strihou, C.; Hirayama, N.; Miyata, T. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 2548-2554.
83. Puchowicz, M.A.; Zechel, J.L.; Valerio, J.; Emancipator, D.S.; Xu, K.; Pundlik, S.; LaManna, J.C.; Lust, W.D. Neuroprotection in diet-induced ketotic rat brain after focal ischemia. J. Cereb. Blood Flow Metab., 2008, 28, 1907-1916.
84. Suzuki, M.; Suzuki, M.; Kitamura, Y.; Mori, S.; Sato, K.; Dohi, S.; Sato, T.; Matsuura, A.; Hiraide, A. Beta-hydroxybutyrate, a cerebral function improving agent, protects rat brain against ischemic damage caused by permanent and transient focal cerebral ischemia. Jpn. J Pharmacol., 2002, 89, 36-43.